TIMP1 and rheumatoid arthritis: The aim of the present study was to evaluate the effects of the administration of rituximab on serum MMPs and TIMP-1 levels and ratios of MMPs to TIMPs in patients with active RA not responding to anti-tumor necrosis factor therapy.